Error bars indicate 95% confidence intervals; CAPRA, Cancer of the Prostate Risk Assessment.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Cooperberg MR, Carroll PR. Trends in Management for Patients With Localized Prostate Cancer, 1990-2013. JAMA. 2015;314(1):80–82. doi:10.1001/jama.2015.6036
Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
A growing literature supports the safety and efficacy of active surveillance for patients with low-risk prostate cancer. However, the experience behind this literature is based almost entirely in academic centers, and prior reports have consistently found surveillance generally underused in most other settings.1,2 Conversely, high-risk tumors have been undertreated with androgen deprivation treatment alone.2,3 Recent trends in community-based practice patterns have not been well documented.
Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) is a national registry accruing men with prostate cancer diagnosed at 45 urology practices across the United States since 1995. A mix of large and small practices are included. All but 3 are community-based practices and 28 states across all regions are represented. Both prospective enrollment of newly diagnosed men and retrospective enrollment of previously diagnosed men were permitted before 1998; however, since 1998 all enrollment has been prospective.
Approximately 90% of eligible patients are accrued. Urologists report clinical data; patients provide written consent under central institutional review board supervision. Other methodological details have been reported.4 We analyzed men with tumors classified as stage cT3aN0M0 or lower managed with prostatectomy, radiation, androgen deprivation monotherapy, or active surveillance/watchful waiting between 1990 and 2013. Only recently have these 2 terms been clearly separated,1 and CaPSURE has historically recorded them as a single category. There were 656 men (5.9%) with missing treatment data who were excluded.
Cancer risk was stratified using the validated Cancer of the Prostate Risk Assessment (CAPRA) score.5 We analyzed treatment trends over 5-year intervals in the full cohort and in a subset of men aged 75 years or older. We calculated Mantel-Haenszel tests for trends over time. There have been changes in the CaPSURE sites over time (eg, some have closed or withdrawn and others have been added). A subset analysis including only practices steadily contributing patients found substantially similar results. Analyses were performed with Stata version 12.1 (StataCorp). Statistical tests were 2-tailed with α = .05.
Among 10 472 men included, the mean (SD) age was 65.7 (8.8) years. The median CAPRA score was 2 (interquartile range, 1-4). There were 1015 black men (9.7%) and 9111 white men (87.0%). Surveillance use for low-risk disease (CAPRA score range, 0-2) remained low from 1990 through 2009 (varying from 6.7% [95% CI, 5.8%-7.6%] to 14.3% [95% CI, 10.3%-18.3%]), but increased sharply in 2010 through 2013 (to 40.4% [95% CI, 34.9%-45.9%]; P < .001 for trend). Conversely, treatment with androgen deprivation for intermediate-risk and high-risk tumors, which had been increasing steadily from 1990 (9.7% [95% CI, 7.0%-12.3%] and 29.8% [95% CI, 23.3%-36.4%], respectively), decreased sharply (to 3.8% [95% CI, 1.2%-6.4%] and 24.0% [95% CI, 14.1%-33.9%], respectively) (Figure 1).
Among men aged 75 years or older, the rate of surveillance was 54.1% (95% CI, 37.2% to 70.9%) from 1990 through 1994, declined to 21.9% (95% CI, 17.4% to 26.4%) from 2000 through 2004, and increased to 76.2% (95% CI, 56.3% to 96.1%) from 2010 through 2013. There was an increase in the use of surgery for men aged 75 years or older with low-risk cancer to 9.5% (95% CI, −4.1% to 23.2%) and intermediate-risk cancer to 15.0% (95% CI, −2.1% to 32.1%); however, there was not an increase in use for those with high-risk cancer, among whom androgen deprivation still accounted for 66.7% (95% CI, 39.6% to 93.7%) of treatment (Figure 2).
Surveillance rates at individual urology practices ranged from 8.3% to 63.6% (median, 36.0%; interquartile range, 12.7%-54.1%).
In this analysis of a longstanding, national registry, we found that after years of overtreatment for patients with low-risk prostate cancer, rates of active surveillance/watchful waiting for low-risk disease increased sharply in 2010 through 2013. Concurrently, high-risk disease was more often treated appropriately with potentially curative local treatment rather than androgen deprivation alone, although not in men aged 75 years or older. Substantial variation persisted in treatment patterns across individual practices, as observed previously.2,6
The major limitation of the study is that CaPSURE is not a random population sample. However, participating practices do reflect broadly varied characteristics,2 and the patients have previously been shown to be similar to those included in the Surveillance, Epidemiology, and End Results registry in terms of demographics, though CaPSURE patients are more often white and have higher incomes.5
The magnitude and speed of the changes suggest a genuine change in the management of patients with prostate cancer in the United States, which could accelerate as more clinicians begin to participate in registry efforts. Given that overtreatment of low-risk disease is a major driver of arguments against prostate cancer screening efforts, these observations may help inform a renewed discussion regarding early detection policy in the United States.
Corresponding Author: Matthew R. Cooperberg, MD, MPH, Helen Diller Family Comprehensive Cancer Center, Department of Urology, University of California, 550 16th St, San Francisco, CA 94143 (firstname.lastname@example.org).
Author Contributions: Dr Cooperberg had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: All authors.
Acquisition, analysis, or interpretation of data: Cooperberg.
Drafting of the manuscript: Cooperberg.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Cooperberg.
Obtained funding: All authors.
Administrative, technical, or material support: Carroll.
Conflict of Interest Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Cooperberg reported receiving grants and personal fees from Myriad Genetics; receiving grants from Genomic Health and GenomeDx; and receiving personal fees from Dendreon, Astellas, and Bayer. No other disclosures were reported.
Funding/Support: CaPSURE was funded until 2007 by TAP Pharmaceutical Products Inc. It is currently funded by US Department of Defense grant W81XWH-13-2-0074 and the University of California, San Francisco, Department of Urology resources.
Role of the Funder/Sponsor: The sponsor or funding organization had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Create a personal account or sign in to: